Today, a Director at Vital Therapies (NASDAQ: VTL), Cheryl Cohen, sold shares of VTL for $1,925.
See today’s analyst top recommended stocks >>
Currently, Vital Therapies has an average volume of 12.15M.
Based on 4 analyst ratings, the analyst consensus is Hold with an average price target of $0.50, reflecting a 22.0% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vital Therapies, Inc. operates as a biotherapeutic company, which develops a human hepatic cell-based system for the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal.
